Q-omics provides the consensus-scored IGKV1OR2-118 profile across patient tissues and cancer cell-line models. IGKV1OR2-118 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGKV1OR2-118 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, IGKV1OR2-118 RNA expression shows 6,848 significant pathway-activity associations, with the highest sampling consensus in HNSC. Together, these results highlight HNSC, and COAD as cancer lineages where IGKV1OR2-118 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGKV1OR2-118 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGKV1OR2-118 survival associations across molecular data types. IGKV1OR2-118 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGKV1OR2-118 RNA expression–survival associations across cancer types. High IGKV1OR2-118 expression shows unfavorable associations in ACC and STAD, but favorable associations in HNSC, SKCM, MESO and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGKV1OR2-118 RNA expression.
This table summarizes IGKV1OR2-118 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGKV1OR2-118. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGKV1OR2-118 shows lower tumor expression in COAD, STAD, BRCA and READ and higher tumor expression in LUAD and KIRC. The COAD box plot shows higher IGKV1OR2-118 RNA expression in normal versus tumor tissue (log2 FC = −1.535, t-test p < 0.001).
This table shows molecular features associated with IGKV1OR2-118 in patient tissues and cancer cell lines. In patient samples, IGKV1OR2-118 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
